Glaukos Corp (GKOS)vsMerck & Company Inc (MRK)
GKOS
Glaukos Corp
$131.19
+2.72%
HEALTHCARE · Cap: $7.45B
MRK
Merck & Company Inc
$119.60
+0.84%
HEALTHCARE · Cap: $283.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 11829% more annual revenue ($65.77B vs $551.35M). MRK leads profitability with a 13.6% profit margin vs -34.3%. GKOS appears more attractively valued with a PEG of 1.64. MRK earns a higher WallStSmart Score of 50/100 (D+).
GKOS
Hold44
out of 100
Grade: D
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1.2%
Fair Value
$107.76
Current Price
$131.19
$23.43 premium
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$119.60
$38.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 41.2% year-over-year
Earnings expanding 1896.0% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Trading at 11.4x book value
Weak financial health signals
ROE of -28.2% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GKOS
The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : GKOS
The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
GKOS profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
GKOS carries more volatility with a beta of 0.81 — expect wider price swings.
GKOS is growing revenue faster at 41.2% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 44/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Glaukos Corp
HEALTHCARE · MEDICAL DEVICES · USA
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?